Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | XPO1 | O14980 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898366 | 1.00 | PTPN1 (0.40) | PTPN1ATMHTTXPO1KDM4E | |
| SCHEMBL20717935 | 0.81 | CYP1A2 (0.35) | ATM | |
| SCHEMBL4926758 | 0.80 | PTPN1 (0.40) | PTPN1HTTXPO1KDM4ELMNA | |
| SCHEMBL5307393 | 0.80 | PTPN1 (0.40) | PTPN1HTTXPO1KDM4ELMNA | |
| SCHEMBL4917217 | 0.80 | PTPN1 (0.40) | PTPN1HTTXPO1KDM4ELMNA | |
| SCHEMBL28984727 | 0.77 | ATM (0.34) | ATM | |
| SCHEMBL15216845 | 0.77 | PTPN1 (0.38) | PTPN1HTTXPO1KDM4ELMNA | |
| SCHEMBL12834881 | 0.77 | PTPN1 (0.35) | PTPN1HTTXPO1KDM4ELMNA | |
| SCHEMBL10305872 | 0.76 | PTPN1 (0.40) | PTPN1HTTXPO1 | |
| SCHEMBL512370 | 0.76 | XPO1 (0.39) | PTPN1HTTXPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6288141-B1 | Ink compositions | XEROX CORPORATION | 2001-09-11 | — | — | US | claimed |
| US-6132499-A | Inks | XEROX CORPORATION (US) | 2000-10-17 | — | — | US | claimed |
| US-6071333-A | Ink compositions | XEROX CORPORATION (US) | 2000-06-06 | — | — | US | claimed |
| US-6045607-A | FIRST AND SECOND SOLID CARBAMATES WITH A DISSIMILAR MELTING POINTS; LIGHTFASTNESS COMPONENT; A LIGHTFASTNESS ANTIOXIDANTS, AND A COLORANT; USEFUL FOR ACOUSTIC INK PRINTING | XEROX CORPORATION (US) | 2000-04-04 | — | — | US | claimed |
| CN-108148022-B | Andrographolide compound, pharmaceutical composition and application thereof | 江西青峰药业有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | LU ZHONGHUI (US) | 2004-08-19 | — | — | US | disclosed |
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1263755-A2 | CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
| US-6334890-B1 | COMPOSITION COMPRISED OF OXAZOLINE COMPOUND WITH SPECIFIED MELTING POINT AND ACOUSTIC LOSS VALUE, LONG CHAIN CARBAMATE, ALCOHOL COMPOUND, LIGHTFASTNESS COMPONENT, LIGHTFASTNESS ANTIOXIDANT, COLORANT | XEROX CORPORATION | 2002-01-01 | — | — | US | disclosed |
| WO-2001070673-A2 | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6187082-B1 | COMPOSITION COMPRISED OF THIOUREA AND INK CARBAMATE, EACH WITH SPECIFIED MELTING POINT AND ACOUSTIC-LOSS VALUE, LIGHTFASTNESS COMPONENT, LIGHTFAST ANTIOXIDANT, COLORANT | XEROX CORPORATION | 2001-02-13 | — | — | US | disclosed |
| US-6132499-A | Inks | XEROX CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| US-6110265-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| US-6106601-A | MIXTURE CONTAINING OXAZOLINE AND THIOUREA COMPOUNDS | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | disclosed |
| US-6096125-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-6071333-A | Ink compositions | XEROX CORPORATION (US) | 2000-06-06 | — | — | US | disclosed |
| US-6066200-A | COMPRISING A SOLID UREA COMPOUND, AN ALCOHOL, A LIGHTFASTNESS COMPONENT, A LIGHTFAST ANTIOXIDANT, AND A COLORANT | XEROX CORPORATION (US) | 2000-05-23 | — | — | US | disclosed |
| US-6045607-A | FIRST AND SECOND SOLID CARBAMATES WITH A DISSIMILAR MELTING POINTS; LIGHTFASTNESS COMPONENT; A LIGHTFASTNESS ANTIOXIDANTS, AND A COLORANT; USEFUL FOR ACOUSTIC INK PRINTING | XEROX CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | PTPN1 1597/4885ATM 4425/4885HTT 4753/4885 |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | PTPN1 1597/4885ATM 4425/4885HTT 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.